News | Cath Lab | February 27, 2019

DABRA Excimer Laser System Demonstrates Success in Treating PAD

Study achieved a statistically significant difference in pre- and post-percent stenosis and ankle-brachial index values

DABRA Excimer Laser System Demonstrates Success in Treating PAD

February 27, 2019 — Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s DABRA System for the treatment of above- and below-the-knee peripheral artery disease (PAD). The data was presented by Ashok Kondur, M.D., FACC, FSCAI at the 2019 Leipzig Interventional Course (LINC) in Leipzig, Germany.

The study results were overwhelmingly positive, according to the company, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80 percent of lesions had moderate to severe calcification) and 93 percent median lesion stenosis. A statistically significant difference was demonstrated in pre- and post-diameter stenosis (p<0.001), and lesion success, defined as <30 percent post diameter stenosis, was 98 percent. Furthermore, the results demonstrated statistically significant improvements in limb hemodynamic measures.

“The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Kondur, chair, Division of Cardiology, Garden City Hospital/MSU and associate program director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.

The purpose of the study was to evaluate the use of DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) in patients with above-the-knee and below-the-knee disease in a cohort of 52 patients and 111 collective lesions. Patients were treated solely with DABRA plus percutaneous coronary angioplasty (PTA), with no adjunctive stenting. Intravascular ultrasound and/or angiography was used pre- and post-treatment.

“We have seen significant changes in pre- and post-ABIs [ankle-brachial indices] and a very low complication rate with no distinct clinically or angiographically observed distal embolization,” said study lead investigator Elias Kassab, M.D., FACC, FSCAI, FACP, FASA, RPVI, FAHA, FSVM, president and CEO of Michigan Outpatient Vascular Institute and assistant professor of medicine, Wayne State University.

DABRA is a safe, versatile and simple catheter and laser system for the treatment of mixed morphology vascular blockages above- and below-the-knee. Its photochemical plaque ablating mechanism of action reduces all plaque types (calcium, thrombus and atheroma) into their fundamental chemistry with reduced mechanical, thermal and barometric trauma and minimized downstream debris.

The positive results presented at LIN 2019 are reaffirmed by Athar Ansari, M.D., DTM&H, MRCP, FACC, in his case report, Treatment of a Long, Heavily Calcified left SFA Lesion with Single-Vessel Runoff Via an Ipsilateral Antegrade Approach, published in the January issue of Endovascular Today. In the article, Ansari highlights the product’s fast and easy use with no distal embolization in yet another challenging case.

For more information: www.ramed.com


Related Content

News | ACC

March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the ...

Home April 02, 2026
Home
News | ACC

March 30, 2026 — Helen H. Hobbs, M.D., professor in the Eugene McDermott Center for Human Growth and Development and of ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — At ACC.26 in New Orleans, Esperion presented two post-hoc analyses from CLEAR Outcomes focused on risk ...

Home April 01, 2026
Home
News | ACC

March 30, 2026 — Partho Sengupta, MD, DM, FACC, FASE, was honored as a 2026 Distinguished Scientist (Translational ...

Home March 31, 2026
Home
News | ACC

March 29, 2026 — Medical AI, a company specializing in artificial intelligence-enabled electrocardiogram (ECG) solutions ...

Home March 31, 2026
Home
News | ACC

March 28, 2026 — Randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026 and ...

Home March 30, 2026
Home
News | ACC

March 25, 2026 — At the 75th Annual Scientific Session & Expo of the American College of Cardiology (ACC.26) in New ...

Home March 27, 2026
Home
News | ACC

March 18, 2026 — UltraSight will present six clinical studies validating the performance of its UltraSight Echosystem at ...

Home March 27, 2026
Home
News | ACC

March 25, 2026 — At ACC.26, GE HealthCare will showcase some of its latest solutions that support clinicians across the ...

Home March 26, 2026
Home
News | ACC

March 24, 2026 — Physicians and investigators from the Smidt Heart Institute at Cedars-Sinai will present research and ...

Home March 26, 2026
Home
Subscribe Now